Philadelphia, Pennsylvania


The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated with congenital hyperinsulinism.


Inclusion Criteria: - Clinical diagnosis of congenital hyperinsulinism - Duration of glucose levels less than 70mg/dL, by CGM, for an average of at least 120 minutes a day across baseline Days -3, -2, and -1 with no single duration less than 60 minutes on any of the baseline Days -3, -2, or -1, unless the subject received rescue treatment. - Can safely washout of background medications used to treat hyperinsulinism. Exclusion Criteria: - Use of any agent, such as diazoxide, octreotide, chronic systemic glucocorticoids, or β agonists that may affect glucose metabolism - Body Mass Index ≥ 35 kg/m2 - Pregnant females, females planning to become pregnant during the course of the study, females who have delivered 3 months before screening, or breastfeeding - Male subjects who are planning a pregnancy with a female partner during the course of the study or within 4 months after administration of study drug.



Primary Contact:

Study Director
Allan Gordon, MD, PhD

Ann Neale
Phone: 510-204-7515

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.